Antibodies
3 December 2014
Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration1 December 2014
OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer1 December 2014
EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema1 December 2014
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)28 November 2014
Nippon Kayaku launches Infliximab BS for I.V. Infusion 100mg “NK”, an anti-human TNF-α monoclonal antibody, in Japan26 November 2014
Ablynx demonstrates bioequivalence between liquid and lyophilised formulations of its anti-vWF nanobody, caplacizumab25 November 2014
Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform24 November 2014
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer21 November 2014
Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients20 November 2014
Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy20 November 2014
Kolltan Presents KTN3379 Clinical and Preclinical Data at International Cancer Meeting20 November 2014
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis19 November 2014
Kadmon Corporation Presents Preclinical Data on Bi-Functional Anti-PD-L1/IL-15 Fusion Protein at EORTC-NCI-AACR Symposium19 November 2014
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol19 November 2014
Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual Meeting of the American College of Rheumatology in Boston17 November 2014
MEDIMMUNE PRESENTS POSITIVE PHASE IIB DATA FOR MAVRILIMUMAB IN RHEUMATOID ARTHRITIS AT ACR ANNUAL MEETING17 November 2014
MEDIMMUNE PRESENTS PROMISING NEW DATA IN SYSTEMIC LUPUS AT AMERICAN COLLEGE OF RHEUMATOLOGY MEETING17 November 2014
Novartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studiesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports